Agile Therapeutics Announces Preliminary Expectations for First Quarter 2023
PRINCETON, N.J., April 28, 2023 (GLOBE NEWSWIRE) — Agile Therapeutics, Inc. (Nasdaq:AGRX), a women’s healthcare company, today announced preliminary expectations for first quarter 2023 Twirla® demand, net revenue and operating expenses.
Related news for (AGRX)
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALLG, DM, AGRX on Behalf of Shareholders
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AAN, TBNK, AGRX, UMBF on Behalf of Shareholders
- AGRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Agile Therapeutics, Inc. Is Fair to Shareholders
- Agile Therapeutics Announces Delisting from Nasdaq
- Correction – Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024